143 related articles for article (PubMed ID: 19514121)
1. Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase.
Imai Y; Ohmori K; Yasuda S; Wada M; Suzuki T; Fukuda K; Ueda Y
Cancer Sci; 2009 Jun; 100(6):1118-27. PubMed ID: 19514121
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).
Meyer zu Schwabedissen HE; Grube M; Dreisbach A; Jedlitschky G; Meissner K; Linnemann K; Fusch C; Ritter CA; Völker U; Kroemer HK
Drug Metab Dispos; 2006 Apr; 34(4):524-33. PubMed ID: 16415123
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein.
Katayama K; Yoshioka S; Tsukahara S; Mitsuhashi J; Sugimoto Y
Mol Cancer Ther; 2007 Jul; 6(7):2092-102. PubMed ID: 17620438
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
Imai Y; Ishikawa E; Asada S; Sugimoto Y
Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
[TBL] [Abstract][Full Text] [Related]
6. ABCG2 protects kidney side population cells from hypoxia/reoxygenation injury through activation of the MEK/ERK pathway.
Liu WH; Liu HB; Gao DK; Ge GQ; Zhang P; Sun SR; Wang HM; Liu SB
Cell Transplant; 2013; 22(10):1859-68. PubMed ID: 23032069
[TBL] [Abstract][Full Text] [Related]
7. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
9. Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.
Xie Y; Nakanishi T; Natarajan K; Safren L; Hamburger AW; Hussain A; Ross DD
Biochim Biophys Acta; 2015 Mar; 1849(3):317-27. PubMed ID: 25615818
[TBL] [Abstract][Full Text] [Related]
10. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
11. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
12. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
13. Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines.
Tomiyasu H; Watanabe M; Sugita K; Goto-Koshino Y; Fujino Y; Ohno K; Sugano S; Tsujimoto H
Anticancer Res; 2013 Dec; 33(12):5317-23. PubMed ID: 24324065
[TBL] [Abstract][Full Text] [Related]
14. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P
Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
17. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
Nakanishi T; Bailey-Dell KJ; Hassel BA; Shiozawa K; Sullivan DM; Turner J; Ross DD
Cancer Res; 2006 May; 66(10):5007-11. PubMed ID: 16707421
[TBL] [Abstract][Full Text] [Related]
18. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
[TBL] [Abstract][Full Text] [Related]
19. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
